Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.

ABSTRACT:

Background

Enfortumab vedotin combined with pembrolizumab (EV-P) has become the new standard first-line therapy for patients with advanced urothelial carcinoma (aUC), based on its superior efficacy over platinum-based chemotherapy. As this regimen is increasingly adopted in routine care, treatment decisions may often occur in sites without dedicated genitourinary oncology expertise. This global survey aimed to explore how physicians perceive clinical factors that may influence the safe and effective use of EV-P in daily practice.

Material and methods

A panel of international physicians with experience in treating patients with genitourinary cancers developed a 17-question survey addressing practice settings, experience in managing aUC, and clinical considerations relevant to

SUBMITTER: Grande E 

PROVIDER: S-EPMC12558748 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature